AWARDEES

- **2025 ASCO President-elect**
  Eric Small, MD, FASCO

- **Newly Appointed ASCO Committee Leaders**
  - Amy Jo Chien, MD, Chair-Elect, Annual Meeting Scientific Program Committee
  - Sam Brondfield, MD, MA Chair-Elect, Education Council
  - Niharika Dixit, MD Chair-Elect, Health Policy Committee

- **Featured Voices #ASCO24**
  - Ana I. Velázquez Mañana, MD MS

- **Young Investigator Awards**
  - William S. Chen, MD
  - Lindsey M. Draper, MD
  - Kelsey Natsuhara, MD
  - Michael P. Randall, MD
  - Noah Younger, MD, PhD

- **Annual Meeting Merit Awards**
  - Kirkpatrick Fergus, MD
  - Mulki Mehari,
  - Ali Sabbagh, MD

- **Annual Meeting Research Awards**
  - Kevin Reyes, BS

- **Medical Student Rotation**
  - Kevin Reyes, BS

- **Oncology Summer Internships**
  - Asmaa Mahoui
  - Alvine Ngouonga
  - Maria Gonzalez
  - Pearl Omo-sowho
  - Diego Martinez Mendiola
  - Austine Peng
  - Mallory Shingle
  - Isaac Avila-Vargas

PRESENTATIONS AND POSTER SESSIONS BY DATE

FRIDAY, May 31

1:00 PM CT | E253D | ASCO Artificial Intelligence Community of Practice Meeting

*Brief Panel: Potential priorities of AI CoP and introduction to breakouts*

Julian Hong, MD, MS

6:30 PM CT | Hilton, Blvd Room | Ancillary Educational Event

*Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate Therapies*

Moderator Hope S. Rugo, MD, FASCO
**SATURDAY, June 1**

### PRESENTATIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM CT</td>
<td>S100a</td>
<td>Melanoma/Skin Cancers Case Based Panel</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Promise of Neoadjuvant Immunotherapy Across Solid Tumors</td>
<td>Katy K. Tsai, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MODERATOR: Katy K. Tsai, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Navigating Melanoma Management From Early Stages to Post-Adjuvant Therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>This case-based panel will address multidisciplinary care for patients with stage II melanoma.</td>
<td></td>
</tr>
<tr>
<td>8:00 AM CT</td>
<td>E451</td>
<td>Gynecological Cancer Rapid Oral Abstract Session</td>
<td>Katherine Cynthia Fuh, MD, PhD</td>
</tr>
<tr>
<td>8:30 AM CT</td>
<td></td>
<td>Women in Oncology Panel Talk: Leading From Within: Cultivating Authenticity</td>
<td>Sonya Reid, MD, MPH</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Moderator</strong> Sonya Reid, MD, MPH</td>
<td>Vanderbilt-Ingram Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Panelists</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cathy Eng, MD, FACP, FASCO</td>
<td>Vanderbilt-Ingram Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reshma Jagsi, MD, DPhil</td>
<td>Emory University School of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Katherine Van Loon, MD, MPH</td>
<td>UCSF</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>E450a</td>
<td>Central Nervous System Tumors Clinical Science Symposium</td>
<td>Benjamin Joshua Lerman, MD, MS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abstract: 2099 Longitudinal tumor-wide sampling of glioblastoma reveals diverse genomic drivers of the earliest clonal expansion at diagnosis and recurrence.</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td>S406</td>
<td>Lung Cancer Education Session</td>
<td>Matthew A. Gubens, MD, MS, FASCO</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Metastatic Non–Small Cell Lung Cancer With Oncogene Addiction/Driver Mutation (not EGFR)</td>
<td></td>
</tr>
</tbody>
</table>
SATURDAY, June 1

POSTERS
8:00 AM CT
Hall A | On Demand

### Developmental Therapeutics - Immunotherapy

<table>
<thead>
<tr>
<th>Name</th>
<th>Abstract</th>
<th>Poster Bd #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jordan Guillot, PhD, PharmD</td>
<td>2555</td>
<td>34</td>
</tr>
<tr>
<td>Adil Daud, MD</td>
<td>2575</td>
<td>54</td>
</tr>
</tbody>
</table>

**Abstract:** Constructing adverse event timelines for patients receiving CAR-T therapy using large language models.

**Abstract:** Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy.

### Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

<table>
<thead>
<tr>
<th>Name</th>
<th>Abstract</th>
<th>Poster Bd #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hope S. Rugo, MD, FASCO</td>
<td>3029</td>
<td>174</td>
</tr>
<tr>
<td>Mulki Mehari, B.A.</td>
<td>2048</td>
<td>347</td>
</tr>
</tbody>
</table>

**Abstract:** Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types.

**Abstract:** Can targeting TSP-1 with gabapentin enhance survival in glioblastoma? A 20-year retrospective cohort study.

### Central Nervous System Tumors

<table>
<thead>
<tr>
<th>Name</th>
<th>Abstract</th>
<th>Poster Bd #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arda Demirci, BA</td>
<td>1561</td>
<td>432</td>
</tr>
<tr>
<td>Mulki Mehari, B.A.</td>
<td>2048</td>
<td>347</td>
</tr>
</tbody>
</table>

**Abstract:** Large language models to evaluate racial discrepancies in performance status assignment.

**Abstract:** Can targeting TSP-1 with gabapentin enhance survival in glioblastoma? A 20-year retrospective cohort study.

### Care Delivery/Models of Care

<table>
<thead>
<tr>
<th>Name</th>
<th>Abstract</th>
<th>Poster Bd #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constance Wu, MD, MPhil</td>
<td>1576</td>
<td>447</td>
</tr>
<tr>
<td>Kevin R Reyes, BS</td>
<td>1605</td>
<td>476</td>
</tr>
</tbody>
</table>

**Abstract:** Lessons learned from a genetic counseling randomized clinical trial: Implications for recruiting individuals identifying as Asians in research.

**Abstract:** Unveiling inequities in representation: Racial disparities in supportive care breast cancer clinical trial enrollment.

### Predicting therapeutic clinical trial enrollment for underrepresented patients in neuro-oncology using supervised machine learning.

<table>
<thead>
<tr>
<th>Name</th>
<th>Abstract</th>
<th>Poster Bd #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ana I. Velazquez Manana, MD, MSc, MS</td>
<td>1619</td>
<td>490</td>
</tr>
</tbody>
</table>

**Abstract:** Challenges and solutions to recruiting diverse populations to oncology clinical trials: A mixed-methods study of clinical research coordinators.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Robin Kate Kelley, MD

Abstract: 4022 | Poster Bd #: 2

T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC).
# SUNDAY, June 2

## PRESENTATIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Type</th>
<th>Presentation Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 AM</td>
<td>Education Session</td>
<td>ASCO/AACR Joint Session: Drugging the “Undruggable” Target: Successes, Challenges, and the Road Ahead</td>
</tr>
<tr>
<td></td>
<td>Keven M. Shokat, PhD</td>
<td>The Story of KRAS-Directed Therapy From Bench to Bedside: A Roadmap for Success?</td>
</tr>
<tr>
<td>11:30 AM CT</td>
<td>Rapid Oral Abstract Session</td>
<td>Dev Therapeutics—Immuno</td>
</tr>
<tr>
<td></td>
<td>Zoe Quandt, MD, MS</td>
<td>Abstract: 2516 HLA associations with immunotherapy related endocrine toxicity.</td>
</tr>
</tbody>
</table>
**Breast Cancer—Metastatic**

**Hope S. Rugo, MD, FASCO**
Abstract: 1069 | Poster Bd #: 47
Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.

**Laura Ann Huppert, MD**
Abstract: 1083 | Poster Bd #: 61
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.

**Samantha Catherine Fisch, MD**
Abstract: 1108 | Poster Bd #: 86
A single center retrospective cohort study of patients with metastatic breast cancer and leptomeningeal disease: Updated survival data and subgroup analyses by breast cancer subtype.

**Genitourinary Cancer—Prostate, Testicular, and Penile**

**Ali Sabbagh, MD**
Abstract: 5065 | Poster Bd #: 471
Development of a machine learning model to predict overall survival results from randomized clinical trials of patients with metastatic prostate cancer.

**Nonna Shakhnazaryan, BS**
Abstract: 5066 | Poster Bd #: 472
A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).

**Daniel H Kwon, MD | UCSF**
Abstract: 5105 | Poster Bd #: 511
Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study.
### PRESENTATIONS

**8:00 AM CT | S100bc**  
**Rapid Oral Abstract Session**  
**Central Nervous Sys Tumors**

**John Frederick de Groot, MD**  
**Abstract: 2005**  
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.

**1:15 PM CT | B1**  
**Rapid Oral Abstract Session**  
**Genitourinary Cancer**

**Rahul Raj Aggarwal, MD**  
**Abstract: 5012**  
Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).

**3:00 PM | S100a**  
**Education Session**  
**State of the Art in Gynecologic Cancer: New Drugs and Companion Diagnostics**

**Katherine Fuh, MD, PhD**  
Which Antibody-Drug Conjugates Should We Choose and How Should We Manage Them?

**4:30 PM | S100a**  
**Clinical Science Symposium**  
**Symptom Science/Palliative Care**

**Steven Pantilat, FAAHPM, FACP, MHM**  
Hope Beyond a Cure

### POSTERS

**9:00 AM CT**  
**Hall A | On Demand**

**Care Delivery and Quality Care**

**Amrita B Basu, PhD | UCSF**  
**Abstract: 11113 Poster: 308**  
Evaluation of drug tolerability as a function of toxicity and quality of life in patients enrolled on I SPY2.
### POSTERS

**1:30 PM CT**

**Hall A | On Demand**

<table>
<thead>
<tr>
<th><strong>Lung Cancer</strong></th>
</tr>
</thead>
</table>
| **Turja Chakrabarti, MD, MS**  
Abstract: 8572  
A phase I/Ib study of the aurora kinase A inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer. |

<table>
<thead>
<tr>
<th><strong>Medical Education and Professional Development</strong></th>
</tr>
</thead>
</table>
| **Sam Brondfield, MD, MA**  
Abstract: 9017  
Observing attending physician teaching behaviors during inpatient hematology/oncology consultation. |

<table>
<thead>
<tr>
<th><strong>Prevention, Risk Reduction, and Genetics</strong></th>
</tr>
</thead>
</table>
| Nishwant Swami, MD, MPH, Hospital of the University of Pennsylvania  
*(Scarlett Gomez and Iona Cheng, senior authors)*  
Abstract: 10561  
Associations of prior lung diseases on risk of lung cancer in populations with no smoking history: A systematic review and meta-analysis. |

<table>
<thead>
<tr>
<th><strong>Breast Cancer—Local/Regional/Adjuvant</strong></th>
</tr>
</thead>
</table>
| Roberto Antonio Leon-Ferre, MD | Mayo Clinic  
*(Laura Esserman, senior author)*  
Abstract: 594  
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial. |

| Alexandra Thomas, MD, FACP | Duke Cancer Institute  
*(Laura Esserman, senior author)*  
Abstract: 582  